NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 195 filers reported holding NEVRO CORP in Q1 2017. The put-call ratio across all filers is 0.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $4,720,000 | +3.9% | 40,000 | -24.3% | 1.08% | -9.0% |
| Q3 2019 | $4,545,000 | +44.1% | 52,864 | +5.7% | 1.18% | +23.5% |
| Q2 2019 | $3,154,000 | -68.5% | 50,000 | -68.8% | 0.96% | -75.8% |
| Q1 2019 | $10,002,000 | +524.3% | 160,000 | +835.7% | 3.97% | +296.7% |
| Q1 2017 | $1,602,000 | -73.6% | 17,100 | -79.2% | 1.00% | -57.0% |
| Q2 2016 | $6,063,000 | – | 82,200 | – | 2.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |